F2G Ltd Announces the Appointment of Michael R. Hodges, M.D. to the Board of Directors
Published: Sep 13, 2010
Michael R Hodges, M.D., BSc., MRCP (UK) has 20 years of biopharmaceutical development experience and has worked in both biotechnology and large pharmaceutical companies. Whilst at Pfizer Inc. Dr. Hodges was the development team leader for Vfend™, the gold standard therapy for invasive aspergillosis, as well as working on the Eraxis™ and Diflucan™ antifungal programs. In addition Dr. Hodges worked on the Zithromax™ and HIV portfolio development programs.
Prior to joining industry at Pfizer Inc. in 1990, Dr. Hodges practiced internal medicine in London, UK. 1989-90 he held an appointment through the Medical Research Council (UK), at St Thomas’ Hospital, London, HIV clinical trials unit. From 1992 to 2001 he held honoree positions with East Kent Hospitals University NHS Foundation Trust.
Shane Kelly, Chief Executive of F2G commented “It is with great pleasure that we announce that Michael Hodges has accepted our invitation to join the Board. His track record in the successful development and transition of antifungals to market will be invaluable as F2G continues to advance its portfolio of antifungal agents.”
Dr Richard White, Chairman of the Board added “We are delighted to welcome Michael to the Board. His knowledge and experience in the antifungal sector will be a considerable asset to F2G and I look forward to working with him towards the further development of F2G’s antifungal programs.”
Commenting on his appointment, Dr Michael Hodges said “I am delighted to be joining the Board of Directors, especially at such an exciting time for the company as they move their series of novel antifungal drug candidates into the clinic”.
Registered office: Lankro Way, Eccles, Manchester M30 0BH tel: 0161 785 1270; fax: 0161 785 1273; e-mail: firstname.lastname@example.org; website: www.f2g.com Company registration number: 03578625; VAT number: GB 712680645 ®
About F2G Ltd:
Based in Manchester, UK, F2G Ltd is dedicated to the discovery and development of new and clinically superior drug classes to treat life-threatening systemic fungal infections in at-risk patient populations. The antifungal market is currently estimated at over 6 billion dollars annually and is growing steadily year on year. Market growth is expected to increase with the emergence of new clinical indications in allergies and asthma. The company has impressive internal capabilities, employing a core team of scientists with a unique understanding of the antifungal arena, supported by an experienced management team. F2G operates a flexible business model, building value through the development of a balanced portfolio of antifungal assets across multiple validated TPPs. For more information visit www.f2g.com
Shane Kelly Chief Executive Officer, F2G Ltd
Tel: (+44) 0161 785 1271 Fax: (+44) 0161 785 1273 Email: email@example.com